Skip to main content

2 Result(s)

within Xavier Nicolas Remove this filter Medicine & Public Health Remove this filter

and

  1. Article

    Open Access

    Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)

    This AMEERA-2 study evaluated the pharmacokinetics, efficacy, and safety of the oral selective estrogen receptor degrader amcenestrant as a monotherapy with dose escalation in Japanese postmenopausal women wit...

    Kenji Tamura, Toru Mukohara, Kan Yonemori, Yumiko Kawabata, Xavier Nicolas… in Breast Cancer (2023)

    Download PDF (744 KB) View Article

  2. Article

    Open Access

    Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II

    Alirocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly lowers low-density lipoprotein cholesterol levels.

    Xavier Nicolas, Nassim Djebli, Clémence Rauch, Aurélie Brunet… in Clinical Pharmacokinetics (2019)

    Download PDF (1725 KB) View Article